Hemophilia: How To Please Payers And Secure Market Share
Executive Summary
Pharma companies are bringing forward innovative products that are set to shake up the hemophilia market – but convincing payers that they have substantial benefits over the current standards of care will be a challenge. Real-world data and early conversations with payers will be key, new research has found.
You may also be interested in...
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.
Pfizer Signs On For Sangamo’s Hemophilia A Gene Therapy
Pfizer has turned again to external expertise among US biotechs to find a potential gene therapy for hemophilia A, to add to its two-year collaboration with Spark Therapeutics on a gene therapy for hemophilia B, and beating off strong competition from other suitors in the process.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.